Europe — EMA
Palonossetrom Hikma (Palonosetron)
Palonosetron, the active ingredient in Palonossetrom Hikma, is a serotonin 5-HT3 receptor antagonist presented as a 0.075 mg/1 ml solution for intravenous use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonossetrom Hikma, is a serotonin 5-HT3 receptor antagonist presented as a 0.075 mg/1 ml solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative recovery in adult patients. GNH USA supplies Palonossetrom Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
GNH USA supplies Palonossetrom Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
What is Palonosetron used for?
Palonosetron is employed across several oncology‑related pathways to control nausea and vomiting.
- Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea after surgery. - Radiotherapy‑induced nausea and vomiting: Helps control nausea associated with radiation treatment. - Antiemesis for highly emetogenic chemotherapy: Provides extended protection for regimens with high emetogenic risk. - Antiemesis for moderately moderately emetic chemotherapy: Offers prophylaxis for moderate‑risk regimens.
What are the side effects of Palonosetron?
Palonosetron is generally well‑tolerated, but adverse reactions can occur.
Common Side Effects: - Headache : M - S - .
Serious or Rare Side Effects: - . - .
What precautions apply to Palonosetron?
Palentos
t t.
.
What does Palonosetron interact with?
t .
.
